Home   /  Find a Trial  /  See All TrialsClick to print page Print
 

See All Trials

QuickViews

by Tumor Type:

Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

Sites with evidence of disease:

Triple Negative Breast Cancer
Sites with evidence of disease:


by Trial Type:

 

see All Trials

Sort by zipcode:  

Share

Twitter
Facebook
 
Young Survivors

Improving Fertility Preservation

A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients (NCT01035099)

Summary

Some breast cancer treatments may affect a woman's ability to become pregnant. Women can choose to undergo in vitro fertilization (IVF) prior to chemotherapy or radiation so that they can store their eggs and try to become pregnant at a later date. IVF involves ovarian stimulation and egg retrieval. Conventional ovarian stimulation often results in very high estrogen levels, which may be unsafe for breast cancer patients. Letrozole (Femara®) is an aromatase inhibitor used to treat hormone-sensitive tumors in postmenopausal women. It can reduce estrogen levels during IVF while still allowing for effective ovarian stimulation. This trial will compare the effectiveness of two different ways of administering letrozole during ovarian stimulation in patients who are scheduled to undergo IVF for fertility preservation due to breast cancer.

Sexual and Reproductive Health Study

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (NCT01788839)

Summary

Cancer and its treatment may affect sexual and reproductive health. To help researchers learn more about the problems women face, participants in this study will complete questionnaires on sexuality and pregnancy before, during, and after cancer treatment. The information will be used to help doctors identify which women are most likely to have early menopause or develop sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment. To be eligible for this study a woman must be age 50 or younger, newly diagnosed with breast cancer, and planning on having, or within one month of starting, chemotherapy.

Genetic Testing Decisions In Newly Diagnosed Ashkenazi Women

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer (NCT01386411)

Summary

Women who are diagnosed with breast cancer at a young age and/or who are of Ashkenazi Jewish descent are more likely to carry the BRCA1 or BRCA2 genetic mutation that increases risk for breast and ovarian cancer. Genetic testing for the BRCA1/2 mutation can help women make decisions about their breast cancer treatment. The purpose of this trial is to see whether women prefer having genetic testing before or after their breast cancer surgery. The study will also look at how women feel about their decision at a later date. To be eligible for this trial, participants must be 18 – 50 years old at diagnosis, be of Ashkenazi Jewish descent, and be planning to undergo breast surgery as part of their treatment.

A Study of the Effect Tamoxifen Has on the Ovaries

Investigating the Impact of Tamoxifen Therapy on Ovarian Aging (NCT01384526)

Summary

Research has been conducted on the effect that chemotherapy can have on the ovaries of premenopausal women being treated for early-stage breast cancer. But little is known about the long-term effects that anti-estrogen therapies might have on ovarian function. This information would help breast cancer patients of reproductive age make more informed and empowered decisions regarding their treatment. The purpose of this study is to explore the effect that tamoxifen has on the ovaries of premenopausal women. To be eligible, participants must be diagnosed with stage I-III breast cancer or ductal carcinoma in situ, or determined to be high risk for breast cancer.

The Young Women's Breast Cancer Study

Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study (NCT01468246)

Summary

Young women with breast cancer have unique needs and concerns. The goal of this study is to follow a large group of young women with breast cancer over time to learn more about the types of tumors they develop, the treatments they have, the side effects they experience, and the psychosocial concerns they face. The researchers are also interested in seeing if there is a relationship between tumor biology and patient outcome. To be eligible, participants must have been diagnosed with breast cancer at age 40 or younger.

Breast Cancer in Young Women

Identification of Novel Genetic Risk Factors That Contribute to the Risk for Breast Cancer (NCT00276120)

Summary

Breast cancer is the leading cause of cancer deaths in women 20-39 years of age. The goal of this trial is to identify the genetic factors that distinguish breast cancer in younger women compared to older women. The researchers hope that identifying these genetic factors will lead to new treatments for younger women who have been diagnosed with breast cancer or who are at high-risk for developing the disease. All women who were diagnosed with breast cancer at age 40 or younger (regardless of current age) are eligible to participate. Because all study-related materials will be mailed, participants can live anywhere in the U.S.

  • Participation TimeBlood sample and questionnaire by mail
  • No Visits Required for this TrialNo travel required